Literature DB >> 1458107

Iron dextran and systemic lupus erythematosus.

V M Oh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1458107      PMCID： PMC1883975          DOI： 10.1136/bmj.305.6860.1000-a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  The adverse effect of intravenous iron-dextran in rheumatoid arthritis.

Authors:  P S Reddy; M Lewis
Journal:  Arthritis Rheum       Date:  1969-08

2.  Effect of intravenous iron dextran on rheumatoid synovitis.

Authors:  D R Blake; J Lunec; M Ahern; E F Ring; J Bradfield; J M Gutteridge
Journal:  Ann Rheum Dis       Date:  1985-03       Impact factor: 19.103

3.  Intravenous iron dextran in clinical medicine.

Authors:  R D Hamstra; M H Block; A L Schocket
Journal:  JAMA       Date:  1980-05-02       Impact factor: 56.272
  3 in total
  3 in total

1.  Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.

Authors:  Ugo Salvadori; Fabio Vittadello; Ahmad Al-Khaffaf; Armin Maier; Paola C Cappelletto; Massimo Daves; Bernd Raffeiner
Journal:  Blood Transfus       Date:  2019-12-13       Impact factor: 3.443

Review 2.  Iron Metabolism: An Under Investigated Driver of Renal Pathology in Lupus Nephritis.

Authors:  Ewa Wlazlo; Borna Mehrad; Laurence Morel; Yogesh Scindia
Journal:  Front Med (Lausanne)       Date:  2021-04-12

3.  Iron-dependent epigenetic modulation promotes pathogenic T cell differentiation in lupus.

Authors:  Xiaofei Gao; Yang Song; Jiali Wu; Shuang Lu; Xiaoli Min; Limin Liu; Longyuan Hu; Meiling Zheng; Pei Du; Yaqin Yu; Hai Long; Haijing Wu; Sujie Jia; Di Yu; Qianjin Lu; Ming Zhao
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.